Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in STEMI Patients Undergoing Primary PCI
NCT06564909Phase 2Active, not recruiting
- Sponsor
- Ain Shams University
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of levocarnitine in myocardial reperfusion injury and myocardial infarction (MI) (2 arms), sponsored by Ain Shams University. Primary endpoints: Nitrotyrosine level at 24 hours and Matrix metallopeptidase-2 level at 24 hours. Started Jun 2025; status: active, not recruiting.
02
Drugs
levocarnitine
03
Conditions
myocardial reperfusion injurymyocardial infarction (MI)
Beyond the preview
Go deeper on NCT06564909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06564909.